Alpha-tropomysin (TPM1) Mutation Analysis
The TPM1 gene that encodes alpha-tropomysin is located in the long (q) arm of chromosome 15 at position 22.2. Alpha-tropomysin is expressed in both fast skeletal and cardiac muscle. It belongs to the tropomyosin family, which are highly conserved actin-binding proteins involved in the contractile system both striated and smooth muscles, and the cytoskeleton of non-muscle cells. The function of alpha-tropomyosin is to form a bridge to bind troponin to thin actin filaments and to regulate the calcium-dependent interaction of actin and myosin during muscle contraction. Mutations in this gene are relatively rare causes of familial hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and left ventricular noncompaction (LVNC). Although alpha-tropomyosin is expressed in both cardiac and skeletal muscle, phenotypic expression is dominated by cardiac myopathy, rather than skeletal myopathy. This is believed to be due to the nature of TPM1 mutations, which alter the portions of the alpha-tropomyosin molecule that interact with the cardiac-specific isoform of troponin T. Alterations in Ca2+ sensitivity may also play a role in the tissue-specificity of TPM1 mutations.
HCM is typically inherited as an autosomal dominant genetic heart disorder although autosomal recessive inheritance and de novo mutations have been described. Clinically HCM is characterized by unexplained left ventricular (LV) hypertrophy (thickening) associated with non-dilated ventricular chambers. Pathological features include myocardial fiber hypertrophy, disorganized myocardial cells, interstitial fibrosis and thickened intra-myocardial coronary vessels. The majority of HCM patients are asymptomatic. Only about 25% develop symptom such as dyspnea, syncope, collapse, palpitations, and chest pain. The disorder has inter- and intra-familial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. HCM is the most common cause of sudden cardiac death in young people with the prevalence of 1:500 in the general adult population. The majority of the mutations in HCM are missense, insertion/deletion and frame-shift mutations. Less than 3% of cases of HCM are due to TPM1 mutations.
Dilated cardiomyopathy (DCM) another genetic disease inherited in an autosomal dominant or X-linked manner. DCM is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. DCM is the most common cause of congestive heart failure in young patients, though, conduction impairment, syncope and sudden death may also occur. It affects 1 per 2,500 populations. Many people with dilated cardiomyopathy have no symptoms or only minor symptoms and live a normal life. Other people may develop symptoms such as fatigue, weight loss, fainting, palpitation, chest pain and sudden death. TMP1 mutations account for < 2% of patients with DCM. LVNC is characterized by a pattern of prominent trabecular meshwork and deep intertrabecular recesses communicating with the left ventricular (LV) cavity. LVNC, like other forms of inherited cardiomyopathy, is genetically heterogeneous and can be inherited as an autosomal dominant or X-linked recessive disorder.
- As and aid in diagnosis of familial hypertrophic cardiomyopathy and dilated cardiomyopathy
- To identify at-risk family members, provide reproductive risks as well as preconception/prenatal options
Negative for mutations analyzed (No mutation or pathogenic variant detected)
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- J Muscle Res Cell Motil. 2013;34: 285-94. [PMID: 24005378]
- Eur J Med Genet. 2018;61: 8-10. [PMID: 29024827]
- J Hum Genet. 2016;61: 41-50. [PMID: 26178429]
- J Card Fail. 2012;18: 296-303. [PMID: 22464770]
- Circulation. 2001;103: 65-71. [PMID: 11136687]
- Emery and Rimoin’s Principles and Practice of Medical Genetics, in: Chapter 47, inherited cardiomyopathies, 2013: 1-38. doi:10.1016/b978-0-12-383834-6.00053-7